Global CINV Existing and Pipeline Drugs Market Growth 2025-2031
The global CINV Existing and Pipeline Drugs market size is predicted to grow from US$ 1676 million in 2025 to US$ 2038 million in 2031; it is expected to grow at a CAGR of 3.3% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?CINV Existing and Pipeline Drugs Industry Forecast? looks at past sales and reviews total world CINV Existing and Pipeline Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected CINV Existing and Pipeline Drugs sales for 2025 through 2031. With CINV Existing and Pipeline Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CINV Existing and Pipeline Drugs industry.
This Insight Report provides a comprehensive analysis of the global CINV Existing and Pipeline Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CINV Existing and Pipeline Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global CINV Existing and Pipeline Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CINV Existing and Pipeline Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CINV Existing and Pipeline Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of CINV Existing and Pipeline Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global CINV Existing and Pipeline Drugs market?
What factors are driving CINV Existing and Pipeline Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CINV Existing and Pipeline Drugs market opportunities vary by end market size?
How does CINV Existing and Pipeline Drugs break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?CINV Existing and Pipeline Drugs Industry Forecast? looks at past sales and reviews total world CINV Existing and Pipeline Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected CINV Existing and Pipeline Drugs sales for 2025 through 2031. With CINV Existing and Pipeline Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CINV Existing and Pipeline Drugs industry.
This Insight Report provides a comprehensive analysis of the global CINV Existing and Pipeline Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CINV Existing and Pipeline Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global CINV Existing and Pipeline Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CINV Existing and Pipeline Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CINV Existing and Pipeline Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of CINV Existing and Pipeline Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aloxi
- Zofran Generic
- Kytril Generic
- Emend
- Akynzeo
- SUSTOL
- Rolapitant
- Hospitals
- Specialty Clinics
- Diagnostic Centers Therapeutics
- Hospital Pharmacies
- Drugstores
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro
What is the 10-year outlook for the global CINV Existing and Pipeline Drugs market?
What factors are driving CINV Existing and Pipeline Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CINV Existing and Pipeline Drugs market opportunities vary by end market size?
How does CINV Existing and Pipeline Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CINV Existing and Pipeline Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Country/Region, 2020, 2024 & 2031
2.2 CINV Existing and Pipeline Drugs Segment by Type
2.2.1 Aloxi
2.2.2 Zofran Generic
2.2.3 Kytril Generic
2.2.4 Emend
2.2.5 Akynzeo
2.2.6 SUSTOL
2.2.7 Rolapitant
2.3 CINV Existing and Pipeline Drugs Sales by Type
2.3.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global CINV Existing and Pipeline Drugs Sale Price by Type (2020-2025)
2.4 CINV Existing and Pipeline Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Diagnostic Centers Therapeutics
2.4.4 Hospital Pharmacies
2.4.5 Drugstores
2.5 CINV Existing and Pipeline Drugs Sales by Application
2.5.1 Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global CINV Existing and Pipeline Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global CINV Existing and Pipeline Drugs Breakdown Data by Company
3.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Company (2020-2025)
3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2020-2025)
3.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Company (2020-2025)
3.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2020-2025)
3.3 Global CINV Existing and Pipeline Drugs Sale Price by Company
3.4 Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CINV Existing and Pipeline Drugs Product Location Distribution
3.4.2 Players CINV Existing and Pipeline Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CINV EXISTING AND PIPELINE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic CINV Existing and Pipeline Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic CINV Existing and Pipeline Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global CINV Existing and Pipeline Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas CINV Existing and Pipeline Drugs Sales Growth
4.4 APAC CINV Existing and Pipeline Drugs Sales Growth
4.5 Europe CINV Existing and Pipeline Drugs Sales Growth
4.6 Middle East & Africa CINV Existing and Pipeline Drugs Sales Growth
5 AMERICAS
5.1 Americas CINV Existing and Pipeline Drugs Sales by Country
5.1.1 Americas CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
5.1.2 Americas CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
5.2 Americas CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
5.3 Americas CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CINV Existing and Pipeline Drugs Sales by Region
6.1.1 APAC CINV Existing and Pipeline Drugs Sales by Region (2020-2025)
6.1.2 APAC CINV Existing and Pipeline Drugs Revenue by Region (2020-2025)
6.2 APAC CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
6.3 APAC CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe CINV Existing and Pipeline Drugs by Country
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
7.2 Europe CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
7.3 Europe CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CINV Existing and Pipeline Drugs by Country
8.1.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs
10.3 Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
10.4 Industry Chain Structure of CINV Existing and Pipeline Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CINV Existing and Pipeline Drugs Distributors
11.3 CINV Existing and Pipeline Drugs Customer
12 WORLD FORECAST REVIEW FOR CINV EXISTING AND PIPELINE DRUGS BY GEOGRAPHIC REGION
12.1 Global CINV Existing and Pipeline Drugs Market Size Forecast by Region
12.1.1 Global CINV Existing and Pipeline Drugs Forecast by Region (2026-2031)
12.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global CINV Existing and Pipeline Drugs Forecast by Type (2026-2031)
12.7 Global CINV Existing and Pipeline Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Helsinn
13.2.1 Helsinn Company Information
13.2.2 Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Helsinn Main Business Overview
13.2.5 Helsinn Latest Developments
13.3 Heron Therapeutics
13.3.1 Heron Therapeutics Company Information
13.3.2 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Heron Therapeutics Main Business Overview
13.3.5 Heron Therapeutics Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Tesaro
13.5.1 Tesaro Company Information
13.5.2 Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Tesaro Main Business Overview
13.5.5 Tesaro Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global CINV Existing and Pipeline Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Country/Region, 2020, 2024 & 2031
2.2 CINV Existing and Pipeline Drugs Segment by Type
2.2.1 Aloxi
2.2.2 Zofran Generic
2.2.3 Kytril Generic
2.2.4 Emend
2.2.5 Akynzeo
2.2.6 SUSTOL
2.2.7 Rolapitant
2.3 CINV Existing and Pipeline Drugs Sales by Type
2.3.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global CINV Existing and Pipeline Drugs Sale Price by Type (2020-2025)
2.4 CINV Existing and Pipeline Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Diagnostic Centers Therapeutics
2.4.4 Hospital Pharmacies
2.4.5 Drugstores
2.5 CINV Existing and Pipeline Drugs Sales by Application
2.5.1 Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global CINV Existing and Pipeline Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global CINV Existing and Pipeline Drugs Breakdown Data by Company
3.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Company (2020-2025)
3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2020-2025)
3.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Company (2020-2025)
3.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2020-2025)
3.3 Global CINV Existing and Pipeline Drugs Sale Price by Company
3.4 Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CINV Existing and Pipeline Drugs Product Location Distribution
3.4.2 Players CINV Existing and Pipeline Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CINV EXISTING AND PIPELINE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic CINV Existing and Pipeline Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic CINV Existing and Pipeline Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global CINV Existing and Pipeline Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas CINV Existing and Pipeline Drugs Sales Growth
4.4 APAC CINV Existing and Pipeline Drugs Sales Growth
4.5 Europe CINV Existing and Pipeline Drugs Sales Growth
4.6 Middle East & Africa CINV Existing and Pipeline Drugs Sales Growth
5 AMERICAS
5.1 Americas CINV Existing and Pipeline Drugs Sales by Country
5.1.1 Americas CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
5.1.2 Americas CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
5.2 Americas CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
5.3 Americas CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CINV Existing and Pipeline Drugs Sales by Region
6.1.1 APAC CINV Existing and Pipeline Drugs Sales by Region (2020-2025)
6.1.2 APAC CINV Existing and Pipeline Drugs Revenue by Region (2020-2025)
6.2 APAC CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
6.3 APAC CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe CINV Existing and Pipeline Drugs by Country
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
7.2 Europe CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
7.3 Europe CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa CINV Existing and Pipeline Drugs by Country
8.1.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa CINV Existing and Pipeline Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs
10.3 Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
10.4 Industry Chain Structure of CINV Existing and Pipeline Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CINV Existing and Pipeline Drugs Distributors
11.3 CINV Existing and Pipeline Drugs Customer
12 WORLD FORECAST REVIEW FOR CINV EXISTING AND PIPELINE DRUGS BY GEOGRAPHIC REGION
12.1 Global CINV Existing and Pipeline Drugs Market Size Forecast by Region
12.1.1 Global CINV Existing and Pipeline Drugs Forecast by Region (2026-2031)
12.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global CINV Existing and Pipeline Drugs Forecast by Type (2026-2031)
12.7 Global CINV Existing and Pipeline Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Helsinn
13.2.1 Helsinn Company Information
13.2.2 Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Helsinn Main Business Overview
13.2.5 Helsinn Latest Developments
13.3 Heron Therapeutics
13.3.1 Heron Therapeutics Company Information
13.3.2 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Heron Therapeutics Main Business Overview
13.3.5 Heron Therapeutics Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Tesaro
13.5.1 Tesaro Company Information
13.5.2 Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Tesaro Main Business Overview
13.5.5 Tesaro Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. CINV Existing and Pipeline Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. CINV Existing and Pipeline Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Aloxi
Table 4. Major Players of Zofran Generic
Table 5. Major Players of Kytril Generic
Table 6. Major Players of Emend
Table 7. Major Players of Akynzeo
Table 8. Major Players of SUSTOL
Table 9. Major Players of Rolapitant
Table 10. Global CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 11. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Table 12. Global CINV Existing and Pipeline Drugs Revenue by Type (2020-2025) & ($ million)
Table 13. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2025)
Table 14. Global CINV Existing and Pipeline Drugs Sale Price by Type (2020-2025) & (USD/Kg)
Table 15. Global CINV Existing and Pipeline Drugs Sale by Application (2020-2025) & (Kg)
Table 16. Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2020-2025)
Table 17. Global CINV Existing and Pipeline Drugs Revenue by Application (2020-2025) & ($ million)
Table 18. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2020-2025)
Table 19. Global CINV Existing and Pipeline Drugs Sale Price by Application (2020-2025) & (USD/Kg)
Table 20. Global CINV Existing and Pipeline Drugs Sales by Company (2020-2025) & (Kg)
Table 21. Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2020-2025)
Table 22. Global CINV Existing and Pipeline Drugs Revenue by Company (2020-2025) & ($ millions)
Table 23. Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2020-2025)
Table 24. Global CINV Existing and Pipeline Drugs Sale Price by Company (2020-2025) & (USD/Kg)
Table 25. Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution and Sales Area
Table 26. Players CINV Existing and Pipeline Drugs Products Offered
Table 27. CINV Existing and Pipeline Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global CINV Existing and Pipeline Drugs Sales by Geographic Region (2020-2025) & (Kg)
Table 31. Global CINV Existing and Pipeline Drugs Sales Market Share Geographic Region (2020-2025)
Table 32. Global CINV Existing and Pipeline Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 33. Global CINV Existing and Pipeline Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 34. Global CINV Existing and Pipeline Drugs Sales by Country/Region (2020-2025) & (Kg)
Table 35. Global CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2020-2025)
Table 36. Global CINV Existing and Pipeline Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 37. Global CINV Existing and Pipeline Drugs Revenue Market Share by Country/Region (2020-2025)
Table 38. Americas CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 39. Americas CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2025)
Table 40. Americas CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & ($ millions)
Table 41. Americas CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 42. Americas CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 43. APAC CINV Existing and Pipeline Drugs Sales by Region (2020-2025) & (Kg)
Table 44. APAC CINV Existing and Pipeline Drugs Sales Market Share by Region (2020-2025)
Table 45. APAC CINV Existing and Pipeline Drugs Revenue by Region (2020-2025) & ($ millions)
Table 46. APAC CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 47. APAC CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 48. Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 49. Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & ($ millions)
Table 50. Europe CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 51. Europe CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 52. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 53. Middle East & Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Table 54. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 55. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 56. Key Market Drivers & Growth Opportunities of CINV Existing and Pipeline Drugs
Table 57. Key Market Challenges & Risks of CINV Existing and Pipeline Drugs
Table 58. Key Industry Trends of CINV Existing and Pipeline Drugs
Table 59. CINV Existing and Pipeline Drugs Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. CINV Existing and Pipeline Drugs Distributors List
Table 62. CINV Existing and Pipeline Drugs Customer List
Table 63. Global CINV Existing and Pipeline Drugs Sales Forecast by Region (2026-2031) & (Kg)
Table 64. Global CINV Existing and Pipeline Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Americas CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 66. Americas CINV Existing and Pipeline Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. APAC CINV Existing and Pipeline Drugs Sales Forecast by Region (2026-2031) & (Kg)
Table 68. APAC CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 69. Europe CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 70. Europe CINV Existing and Pipeline Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Middle East & Africa CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 72. Middle East & Africa CINV Existing and Pipeline Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 73. Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2026-2031) & (Kg)
Table 74. Global CINV Existing and Pipeline Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 75. Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2026-2031) & (Kg)
Table 76. Global CINV Existing and Pipeline Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 77. GlaxoSmithKline Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 79. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 80. GlaxoSmithKline Main Business
Table 81. GlaxoSmithKline Latest Developments
Table 82. Helsinn Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 84. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 85. Helsinn Main Business
Table 86. Helsinn Latest Developments
Table 87. Heron Therapeutics Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 89. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 90. Heron Therapeutics Main Business
Table 91. Heron Therapeutics Latest Developments
Table 92. Merck Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 94. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 95. Merck Main Business
Table 96. Merck Latest Developments
Table 97. Tesaro Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 99. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 100. Tesaro Main Business
Table 101. Tesaro Latest Developments
Table 1. CINV Existing and Pipeline Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. CINV Existing and Pipeline Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Aloxi
Table 4. Major Players of Zofran Generic
Table 5. Major Players of Kytril Generic
Table 6. Major Players of Emend
Table 7. Major Players of Akynzeo
Table 8. Major Players of SUSTOL
Table 9. Major Players of Rolapitant
Table 10. Global CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 11. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Table 12. Global CINV Existing and Pipeline Drugs Revenue by Type (2020-2025) & ($ million)
Table 13. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2025)
Table 14. Global CINV Existing and Pipeline Drugs Sale Price by Type (2020-2025) & (USD/Kg)
Table 15. Global CINV Existing and Pipeline Drugs Sale by Application (2020-2025) & (Kg)
Table 16. Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2020-2025)
Table 17. Global CINV Existing and Pipeline Drugs Revenue by Application (2020-2025) & ($ million)
Table 18. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2020-2025)
Table 19. Global CINV Existing and Pipeline Drugs Sale Price by Application (2020-2025) & (USD/Kg)
Table 20. Global CINV Existing and Pipeline Drugs Sales by Company (2020-2025) & (Kg)
Table 21. Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2020-2025)
Table 22. Global CINV Existing and Pipeline Drugs Revenue by Company (2020-2025) & ($ millions)
Table 23. Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2020-2025)
Table 24. Global CINV Existing and Pipeline Drugs Sale Price by Company (2020-2025) & (USD/Kg)
Table 25. Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution and Sales Area
Table 26. Players CINV Existing and Pipeline Drugs Products Offered
Table 27. CINV Existing and Pipeline Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global CINV Existing and Pipeline Drugs Sales by Geographic Region (2020-2025) & (Kg)
Table 31. Global CINV Existing and Pipeline Drugs Sales Market Share Geographic Region (2020-2025)
Table 32. Global CINV Existing and Pipeline Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 33. Global CINV Existing and Pipeline Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 34. Global CINV Existing and Pipeline Drugs Sales by Country/Region (2020-2025) & (Kg)
Table 35. Global CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2020-2025)
Table 36. Global CINV Existing and Pipeline Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 37. Global CINV Existing and Pipeline Drugs Revenue Market Share by Country/Region (2020-2025)
Table 38. Americas CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 39. Americas CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2025)
Table 40. Americas CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & ($ millions)
Table 41. Americas CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 42. Americas CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 43. APAC CINV Existing and Pipeline Drugs Sales by Region (2020-2025) & (Kg)
Table 44. APAC CINV Existing and Pipeline Drugs Sales Market Share by Region (2020-2025)
Table 45. APAC CINV Existing and Pipeline Drugs Revenue by Region (2020-2025) & ($ millions)
Table 46. APAC CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 47. APAC CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 48. Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 49. Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & ($ millions)
Table 50. Europe CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 51. Europe CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 52. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
Table 53. Middle East & Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Table 54. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type (2020-2025) & (Kg)
Table 55. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application (2020-2025) & (Kg)
Table 56. Key Market Drivers & Growth Opportunities of CINV Existing and Pipeline Drugs
Table 57. Key Market Challenges & Risks of CINV Existing and Pipeline Drugs
Table 58. Key Industry Trends of CINV Existing and Pipeline Drugs
Table 59. CINV Existing and Pipeline Drugs Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. CINV Existing and Pipeline Drugs Distributors List
Table 62. CINV Existing and Pipeline Drugs Customer List
Table 63. Global CINV Existing and Pipeline Drugs Sales Forecast by Region (2026-2031) & (Kg)
Table 64. Global CINV Existing and Pipeline Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Americas CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 66. Americas CINV Existing and Pipeline Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. APAC CINV Existing and Pipeline Drugs Sales Forecast by Region (2026-2031) & (Kg)
Table 68. APAC CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 69. Europe CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 70. Europe CINV Existing and Pipeline Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Middle East & Africa CINV Existing and Pipeline Drugs Sales Forecast by Country (2026-2031) & (Kg)
Table 72. Middle East & Africa CINV Existing and Pipeline Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 73. Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2026-2031) & (Kg)
Table 74. Global CINV Existing and Pipeline Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 75. Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2026-2031) & (Kg)
Table 76. Global CINV Existing and Pipeline Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 77. GlaxoSmithKline Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 79. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 80. GlaxoSmithKline Main Business
Table 81. GlaxoSmithKline Latest Developments
Table 82. Helsinn Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 84. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 85. Helsinn Main Business
Table 86. Helsinn Latest Developments
Table 87. Heron Therapeutics Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 89. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 90. Heron Therapeutics Main Business
Table 91. Heron Therapeutics Latest Developments
Table 92. Merck Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 94. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 95. Merck Main Business
Table 96. Merck Latest Developments
Table 97. Tesaro Basic Information, CINV Existing and Pipeline Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications
Table 99. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 100. Tesaro Main Business
Table 101. Tesaro Latest Developments
LIST OF FIGURES
Figure 1. Picture of CINV Existing and Pipeline Drugs
Figure 2. CINV Existing and Pipeline Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CINV Existing and Pipeline Drugs Sales Growth Rate 2020-2031 (Kg)
Figure 7. Global CINV Existing and Pipeline Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. CINV Existing and Pipeline Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2024)
Figure 10. CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Aloxi
Figure 12. Product Picture of Zofran Generic
Figure 13. Product Picture of Kytril Generic
Figure 14. Product Picture of Emend
Figure 15. Product Picture of Akynzeo
Figure 16. Product Picture of SUSTOL
Figure 17. Product Picture of Rolapitant
Figure 18. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2025
Figure 19. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2025)
Figure 20. CINV Existing and Pipeline Drugs Consumed in Hospitals
Figure 21. Global CINV Existing and Pipeline Drugs Market: Hospitals (2020-2025) & (Kg)
Figure 22. CINV Existing and Pipeline Drugs Consumed in Specialty Clinics
Figure 23. Global CINV Existing and Pipeline Drugs Market: Specialty Clinics (2020-2025) & (Kg)
Figure 24. CINV Existing and Pipeline Drugs Consumed in Diagnostic Centers Therapeutics
Figure 25. Global CINV Existing and Pipeline Drugs Market: Diagnostic Centers Therapeutics (2020-2025) & (Kg)
Figure 26. CINV Existing and Pipeline Drugs Consumed in Hospital Pharmacies
Figure 27. Global CINV Existing and Pipeline Drugs Market: Hospital Pharmacies (2020-2025) & (Kg)
Figure 28. CINV Existing and Pipeline Drugs Consumed in Drugstores
Figure 29. Global CINV Existing and Pipeline Drugs Market: Drugstores (2020-2025) & (Kg)
Figure 30. Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2024)
Figure 31. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application in 2025
Figure 32. CINV Existing and Pipeline Drugs Sales by Company in 2025 (Kg)
Figure 33. Global CINV Existing and Pipeline Drugs Sales Market Share by Company in 2025
Figure 34. CINV Existing and Pipeline Drugs Revenue by Company in 2025 ($ millions)
Figure 35. Global CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2025
Figure 36. Global CINV Existing and Pipeline Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global CINV Existing and Pipeline Drugs Revenue Market Share by Geographic Region in 2025
Figure 38. Americas CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 39. Americas CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 40. APAC CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 41. APAC CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 42. Europe CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 43. Europe CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 45. Middle East & Africa CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 46. Americas CINV Existing and Pipeline Drugs Sales Market Share by Country in 2025
Figure 47. Americas CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Figure 48. Americas CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 49. Americas CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 50. United States CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC CINV Existing and Pipeline Drugs Sales Market Share by Region in 2025
Figure 55. APAC CINV Existing and Pipeline Drugs Revenue Market Share by Region (2020-2025)
Figure 56. APAC CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 57. APAC CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 58. China CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. India CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. China Taiwan CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country in 2025
Figure 66. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Figure 67. Europe CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 68. Europe CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 69. Germany CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. France CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. UK CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 76. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 77. Egypt CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 80. Turkey CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs in 2025
Figure 83. Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
Figure 84. Industry Chain Structure of CINV Existing and Pipeline Drugs
Figure 85. Channels of Distribution
Figure 86. Global CINV Existing and Pipeline Drugs Sales Market Forecast by Region (2026-2031)
Figure 87. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 88. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 89. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 90. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 91. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of CINV Existing and Pipeline Drugs
Figure 2. CINV Existing and Pipeline Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CINV Existing and Pipeline Drugs Sales Growth Rate 2020-2031 (Kg)
Figure 7. Global CINV Existing and Pipeline Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. CINV Existing and Pipeline Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2024)
Figure 10. CINV Existing and Pipeline Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Aloxi
Figure 12. Product Picture of Zofran Generic
Figure 13. Product Picture of Kytril Generic
Figure 14. Product Picture of Emend
Figure 15. Product Picture of Akynzeo
Figure 16. Product Picture of SUSTOL
Figure 17. Product Picture of Rolapitant
Figure 18. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2025
Figure 19. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2025)
Figure 20. CINV Existing and Pipeline Drugs Consumed in Hospitals
Figure 21. Global CINV Existing and Pipeline Drugs Market: Hospitals (2020-2025) & (Kg)
Figure 22. CINV Existing and Pipeline Drugs Consumed in Specialty Clinics
Figure 23. Global CINV Existing and Pipeline Drugs Market: Specialty Clinics (2020-2025) & (Kg)
Figure 24. CINV Existing and Pipeline Drugs Consumed in Diagnostic Centers Therapeutics
Figure 25. Global CINV Existing and Pipeline Drugs Market: Diagnostic Centers Therapeutics (2020-2025) & (Kg)
Figure 26. CINV Existing and Pipeline Drugs Consumed in Hospital Pharmacies
Figure 27. Global CINV Existing and Pipeline Drugs Market: Hospital Pharmacies (2020-2025) & (Kg)
Figure 28. CINV Existing and Pipeline Drugs Consumed in Drugstores
Figure 29. Global CINV Existing and Pipeline Drugs Market: Drugstores (2020-2025) & (Kg)
Figure 30. Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2024)
Figure 31. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application in 2025
Figure 32. CINV Existing and Pipeline Drugs Sales by Company in 2025 (Kg)
Figure 33. Global CINV Existing and Pipeline Drugs Sales Market Share by Company in 2025
Figure 34. CINV Existing and Pipeline Drugs Revenue by Company in 2025 ($ millions)
Figure 35. Global CINV Existing and Pipeline Drugs Revenue Market Share by Company in 2025
Figure 36. Global CINV Existing and Pipeline Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global CINV Existing and Pipeline Drugs Revenue Market Share by Geographic Region in 2025
Figure 38. Americas CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 39. Americas CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 40. APAC CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 41. APAC CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 42. Europe CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 43. Europe CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa CINV Existing and Pipeline Drugs Sales 2020-2025 (Kg)
Figure 45. Middle East & Africa CINV Existing and Pipeline Drugs Revenue 2020-2025 ($ millions)
Figure 46. Americas CINV Existing and Pipeline Drugs Sales Market Share by Country in 2025
Figure 47. Americas CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Figure 48. Americas CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 49. Americas CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 50. United States CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC CINV Existing and Pipeline Drugs Sales Market Share by Region in 2025
Figure 55. APAC CINV Existing and Pipeline Drugs Revenue Market Share by Region (2020-2025)
Figure 56. APAC CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 57. APAC CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 58. China CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. India CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. China Taiwan CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country in 2025
Figure 66. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2025)
Figure 67. Europe CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 68. Europe CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 69. Germany CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. France CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. UK CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
Figure 76. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
Figure 77. Egypt CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 80. Turkey CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries CINV Existing and Pipeline Drugs Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs in 2025
Figure 83. Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
Figure 84. Industry Chain Structure of CINV Existing and Pipeline Drugs
Figure 85. Channels of Distribution
Figure 86. Global CINV Existing and Pipeline Drugs Sales Market Forecast by Region (2026-2031)
Figure 87. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 88. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 89. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 90. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 91. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Biopsy Guidance Systems Market Growth 2023-2029
US$ 3,660.00
March 2023
95 pages
Global Non-alcoholic Steatohepatitis Market Growth 2023-2029
US$ 3,660.00
February 2023
118 pages
Global LED Dermatoscopes Market Growth 2023-2029
US$ 3,660.00
February 2023
107 pages
Global Medical Plasma Expressors Market Growth 2024-2030
US$ 3,660.00
December 2024
97 pages
Global Postpartum Depression Therapeutics Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
93 pages
